PrevaLence of Albuminuria in Patients With CARdiovascular Disease and Type 2 Diabetes Mellitus in China: a National Cross-sectional Study
NCT ID: NCT06336239
Last Updated: 2024-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
3000 participants
OBSERVATIONAL
2023-12-21
2024-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Feature and Outcome of Angiographic Coronary Artery Disease in Chronic Kidney Disease Patients
NCT00651521
CRP to Serum Albumin Ratio in Type 2 DM é Diabetic Nephropathy
NCT05681286
Prevention In Community Clinics From Diabetic Kidney Disease
NCT04988581
Normoalbuminuric Chronic Kidney Disease in Type 2 Diabetes
NCT04411342
Prevalence of Chronic Kidney Disease and Its Association With Clinical Outcome in Patients With Coronary Heart Disease
NCT02509013
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed T2DM combined with ≥1 CVD (hypertension, coronary heart disease, atrial fibrillation, heart failure);
* During the data collection period, they went to the outpatient clinic of the cardiology department of the research center, or received treatment in the cardiology department;
* Ability to self-sign informed consent (electronic /paper).
Exclusion Criteria
* Dialysis patients;
* Other diseases that lead to elevated albuminuria, such as severe infection, confirmed primary glomerular disease, etc.;
. Malignant tumors being treated (surgery, chemotherapy, radiotherapy or targeted therapy);
* Cachexia (CSS score ≥ 5 points);
* Severe liver disease (Child- Pugh grade C) ;
* Participated in an interventional clinical trial in the past three months.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Anzhen Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chang sheng Ma
Director of Cardiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Changsheng Ma, Doctor
Role: PRINCIPAL_INVESTIGATOR
Beijing Anzhen Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Sixth Hospital
Beijing, Beijing Municipality, China
Fangshan District First Hospital
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Chinese PLA Army Characteristic Medical Center
Chongqing, Chongqing Municipality, China
Haidong City Second People's Hospital
Haidong, Gansu, China
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Ruyang County People's Hospita
Luoyang, Henan, China
Luoyang Sixth People's Hospita
Luoyang, Henan, China
Yongcheng People's Hospital
Yongcheng, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Zhangjiagang Sixth People's Hospital
Zhangjiagang, Jiangsu, China
Shenyang Ninth People's Hospital
Shenyang, Liaoning, China
Shenyang Tenth People's Hospital
Shenyang, Liaoning, China
Jining First People's Hospital
Jining, Shandong, China
Tai'an First People's Hospital
Tai’an, Shandong, China
Weihai Central Hospital
Weihai, Shandong, China
Jing'an District Central Hospital of Shanghai
Shanghai, Shanghai Municipality, China
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Zhongshan Hospital Fudan University Qingpu Branch
Shanghai, Shanghai Municipality, China
Qinyuan County People's Hospital
Changzhi, Shanxi, China
Shanxi Bethune Hospital
Taiyuan, Shanxi, China
The First Affiliated Hospital of Xi'an Jiaotong University
XI Ail, Shanxi, China
The Fifth People's Hospital of Sichuan Province
Chengdu, Sichuan, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Taizhou Central Hospital
Taizhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Yu Kong, Doctor
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lei Dong
Role: primary
Haiyan Xu
Role: primary
Chen Liu
Role: primary
Yanna Song
Role: primary
Zhanying Han
Role: primary
Changjie Ren
Role: primary
Yufeng Wang
Role: primary
Zuyi Yuan
Role: primary
Xiaojuan Zhang
Role: primary
Yong Peng
Role: primary
Xiang Ma
Role: primary
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KS2023097
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.